The Notch signaling pathway acts in both physiological and pathological conditions,
including embryonic development and tumorigenesis. In cancer progression, diverse …

Estrogens and estrogen receptors (ERs) regulate metabolism in both normal physiology and
in disease. The metabolic characteristics of intrinsic breast cancer subtypes change based …

Tumor hypoxia is associated with poor patient outcomes in estrogen receptor-α–positive
(ERα+) breast cancer. Hypoxia is known to affect tumor growth by reprogramming …

Background While hypoxia has been well-studied in various tumor microenvironments, its
role in cancer cell dormancy is poorly understood, in part due to a lack of well-established in …

Tamoxifen is a first-line therapeutic drug for oestrogen-receptor positive breast cancer;
however, like other therapeutics, its clinical use is limited by acquired resistance. Tamoxifen …

Medulloblastomas are among the most frequently diagnosed pediatric solid tumors, and
drug resistance remains as the principal cause of treatment failure. Hypoxia and the …

The clinical studies for breast cancer (BC) are now assessing the efficacy of 2-
Methoxyestradiol (2-ME), a naturally occurring derivative of estradiol. Our study aimed to …

Endocrine therapy is a standard treatment offered to patients with ERα (estrogen receptor α)-
positive breast cancer. In endocrine therapy, ERα is either directly targeted by anti-estrogens …

Abstract Quinazolinones, particularly 9-azaglycophymines, and closely related derivatives
and precursors were tested in vitro against various breast cancer cell lines representing the …

Hypoxia is a common feature in solid tumors. Clinical samples show a positive correlation
between the expression of the hypoxia-inducible factor HIF-1α and estrogen receptor alpha …